Avacta's Salivary Gland Cancer Therapy Shows Efficacy in Early-stage Study

04:42 AM EST, 12/17/2025 (MT Newswires) -- Avacta Group (AVCT.L) on Wednesday reported "favorable" preliminary efficacy data for the phase 1b trial of faridoxorubicin in salivary gland cancer, with the drug showing clinically meaningful tumor reduction among the patients. The clinical study enrolled patients who were treatment-naïve or failed earlier lines of therapy. The combined disease control rate for patients in both phase 1a and phase 1b trials was at 90%. The biopharmaceutical company expects to provide additional early-stage data in the first half of 2026.